CERVOMED INC (CRVO) Stock Price, Quote, News and Overview
NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock
CRVO Quote and Key Statistics
CERVOMED INC
NASDAQ:CRVO (1/22/2025, 1:49:00 PM)
2.21
+0.03 (+1.38%)
CRVO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.44% | ||
| ROE | -26.18% | ||
| Debt/Equity | 0 |
CRVO Performance and Technical Analysis
CRVO Ownership and Analysts
CRVO Latest News and Analysis
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for...
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility, balance, a
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and...
Friday Sector Leaders: Biotechnology, Apparel Stores
About CRVO
Company Profile
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-11-09. The company is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. The company is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Company Info
CERVOMED INC
20 Park Plaza, Suite 424
Boston MASSACHUSETTS US
Employees: 8
Company Website: https://cervomed.com/
Phone: 16177444400
CRVO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.87 | 301.48B | ||
| AMGN | AMGEN INC | 14.27 | 147.47B | ||
| GILD | GILEAD SCIENCES INC | 21.04 | 116.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 843.33 | 110.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.09 | 75.33B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.29B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.21B | ||
| NTRA | NATERA INC | N/A | 22.72B | ||
| BIIB | BIOGEN INC | 8.75 | 20.82B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.37B |